Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like Asterias Biotherapeutics Extends The Expiration Date Of Certain Warrants And Provides Update On Cash Position February 2, 2017 Quest Diagnostics Declares Quarterly Cash Dividend August 17, 2017 Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives October 12, 2017
Asterias Biotherapeutics Extends The Expiration Date Of Certain Warrants And Provides Update On Cash Position February 2, 2017
